AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD

AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029.